Why is Glaxosmi. Pharma falling/rising?

As of 01-Aug, Glaxosmithkline Pharmaceuticals Ltd is experiencing a decline in its stock price, currently at 2,933.90, reflecting a decrease of 227.4 points or 7.19%. The stock has underperformed its sector by 4.03% today and has been on a downward trend, losing 8.17% over the last two days. Additionally, the stock has shown significant volatility with an intraday fluctuation of 6.09%. Over the past week, it has dropped by 7.00%, and in the last month, it has fallen by 12.84%. Despite a strong year-to-date performance of 30.59%, the recent downturn contrasts sharply with its longer-term gains, such as a 105.90% increase over the past three years. The company maintains a high management efficiency with a return on equity of 42.32% and a low debt-to-equity ratio, which are positive factors that could support the stock in the long run.
Broader Market Context: The broader market, represented by the Sensex, has also faced challenges, with a decline of 1.06% over the past week and 3.70% over the past month. While Glaxosmithkline Pharmaceuticals has outperformed the market over the past year with a return of 6.60%, the recent performance indicates a divergence, as the stock has significantly underperformed relative to the benchmark in the short term. The pharmaceuticals and drugs sector has also seen a decline of 3.27%, contributing to the negative sentiment surrounding the stock. Furthermore, a decrease in investor participation, as evidenced by a 29.46% drop in delivery volume, suggests waning interest, which may be exacerbating the stock's recent price decline.